Cargando…

The role of glatiramer acetate in the early treatment of multiple sclerosis

The treatment of the underlying disease process causing multiple sclerosis has continued to evolve since the initial approval of interferon-beta-1b in 1993. Current emphasis is on early treatment, including treatment after a single clinical attack (clinically isolated syndrome). The assessment of wh...

Descripción completa

Detalles Bibliográficos
Autor principal: Brandes, David W
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2898171/
https://www.ncbi.nlm.nih.gov/pubmed/20628633
_version_ 1782183483532115968
author Brandes, David W
author_facet Brandes, David W
author_sort Brandes, David W
collection PubMed
description The treatment of the underlying disease process causing multiple sclerosis has continued to evolve since the initial approval of interferon-beta-1b in 1993. Current emphasis is on early treatment, including treatment after a single clinical attack (clinically isolated syndrome). The assessment of which disease modifying medication to use as initial therapy has continued to remain a combination of science and the art of medicine. Equally important are the assessment of treatment failure and the subsequent choice of medication change. This article will present scientific information, as well as information about clinical decision making, about these choices, with emphasis on the changing role of glatiramer acetate in this process.
format Text
id pubmed-2898171
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-28981712010-07-13 The role of glatiramer acetate in the early treatment of multiple sclerosis Brandes, David W Neuropsychiatr Dis Treat Expert Opinion The treatment of the underlying disease process causing multiple sclerosis has continued to evolve since the initial approval of interferon-beta-1b in 1993. Current emphasis is on early treatment, including treatment after a single clinical attack (clinically isolated syndrome). The assessment of which disease modifying medication to use as initial therapy has continued to remain a combination of science and the art of medicine. Equally important are the assessment of treatment failure and the subsequent choice of medication change. This article will present scientific information, as well as information about clinical decision making, about these choices, with emphasis on the changing role of glatiramer acetate in this process. Dove Medical Press 2010 2010-06-24 /pmc/articles/PMC2898171/ /pubmed/20628633 Text en © 2010 Brandes publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Expert Opinion
Brandes, David W
The role of glatiramer acetate in the early treatment of multiple sclerosis
title The role of glatiramer acetate in the early treatment of multiple sclerosis
title_full The role of glatiramer acetate in the early treatment of multiple sclerosis
title_fullStr The role of glatiramer acetate in the early treatment of multiple sclerosis
title_full_unstemmed The role of glatiramer acetate in the early treatment of multiple sclerosis
title_short The role of glatiramer acetate in the early treatment of multiple sclerosis
title_sort role of glatiramer acetate in the early treatment of multiple sclerosis
topic Expert Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2898171/
https://www.ncbi.nlm.nih.gov/pubmed/20628633
work_keys_str_mv AT brandesdavidw theroleofglatirameracetateintheearlytreatmentofmultiplesclerosis
AT brandesdavidw roleofglatirameracetateintheearlytreatmentofmultiplesclerosis